Andrew Baum
Stock Analyst at Citigroup
(2.89)
# 1,526
Out of 5,154 analysts
67
Total ratings
76.74%
Success rate
15%
Average return
Main Sectors:
Stocks Rated by Andrew Baum
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $53 → $60 | $60.29 | -0.48% | 15 | Jan 27, 2026 | |
| PFE Pfizer | Maintains: Neutral | $25 → $26 | $27.05 | -3.88% | 11 | Aug 6, 2025 | |
| MRK Merck & Co. | Maintains: Buy | $125 → $115 | $115.79 | -0.68% | 13 | Feb 5, 2025 | |
| RPRX Royalty Pharma | Maintains: Buy | $60 → $40 | $45.41 | -11.91% | 2 | Oct 25, 2024 | |
| ABBV AbbVie | Maintains: Buy | $170 → $215 | $230.11 | -6.57% | 10 | Oct 25, 2024 | |
| LLY Eli Lilly and Company | Maintains: Buy | $675 → $895 | $990.33 | -9.63% | 11 | Apr 2, 2024 | |
| ALVO Alvotech | Upgrades: Neutral | $5 → $10 | $4.01 | +149.38% | 3 | Oct 20, 2023 | |
| GSK GSK plc | Downgrades: Neutral | n/a | $54.51 | - | 2 | Jul 5, 2017 |
Bristol-Myers Squibb Company
Jan 27, 2026
Maintains: Neutral
Price Target: $53 → $60
Current: $60.29
Upside: -0.48%
Pfizer
Aug 6, 2025
Maintains: Neutral
Price Target: $25 → $26
Current: $27.05
Upside: -3.88%
Merck & Co.
Feb 5, 2025
Maintains: Buy
Price Target: $125 → $115
Current: $115.79
Upside: -0.68%
Royalty Pharma
Oct 25, 2024
Maintains: Buy
Price Target: $60 → $40
Current: $45.41
Upside: -11.91%
AbbVie
Oct 25, 2024
Maintains: Buy
Price Target: $170 → $215
Current: $230.11
Upside: -6.57%
Eli Lilly and Company
Apr 2, 2024
Maintains: Buy
Price Target: $675 → $895
Current: $990.33
Upside: -9.63%
Alvotech
Oct 20, 2023
Upgrades: Neutral
Price Target: $5 → $10
Current: $4.01
Upside: +149.38%
GSK plc
Jul 5, 2017
Downgrades: Neutral
Price Target: n/a
Current: $54.51
Upside: -